BGI Diagnostics is a subsidiary unit of BGI. Our aim is to apply our high genetic research capacity and well-developed global network to solving current health issues worldwide. We are committed to raising genetic health awareness and reducing the rate of major disease by offering a broad array of accurate, reliable and affordable genetic tests and molecular diagnostics services.
Our market leading non-invasive prenatal test (NIPT), the NIFTY™ test, is offered by over 2000 partners in more than 50 countries across the world. As of August 2014, we have processed over 350,000 test samples, making NIFTY™ the world’s most trusted NIPT.
Our product portfolio also includes the below test families:
Vista™ – carrier screening tests
Nova™ – newborn screening tests
Sentis™ – screening tests and targeted treatment tests for cancer
Please visit www.bgidx.com for more information.
BGI, founded in 1999 with the vision of using genomics to benefit the human race, is now the world’s largest genomics organisation.
BGI includes both private non-profit research institutes and sequencing application commercial units. Together with its affiliated offshoots, BGI Americas and BGI Europe, BGI has established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, to support a variety of healthcare, agricultural, environmental and related applications.
Through a combination of high-throughput, cost-effective genomics platforms, its large sample collection and storage capability, in-depth bioinformatics analysis and a core commitment to education, BGI is dedicated to ensuring that omics science and technology can be made to work for the benefit of everyone.